273 related articles for article (PubMed ID: 34767690)
1. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
Davidov Y; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Levy I; Levin EG; Lustig Y; Mor O; Rahav G; Ben Ari Z
Liver Transpl; 2022 Feb; 28(2):215-223. PubMed ID: 34767690
[TBL] [Abstract][Full Text] [Related]
2. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
[TBL] [Abstract][Full Text] [Related]
3. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients.
Guarino M; Esposito I; Portella G; Cossiga V; Loperto I; Tortora R; Cennamo M; Capasso M; Terracciano D; Galeota Lanza A; Di Somma S; Picciotto FP; Morisco F;
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1534-1541.e4. PubMed ID: 35066136
[TBL] [Abstract][Full Text] [Related]
4. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
5. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
Front Immunol; 2022; 13():832501. PubMed ID: 35281023
[TBL] [Abstract][Full Text] [Related]
6. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
[TBL] [Abstract][Full Text] [Related]
7. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
8. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
9. Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.
Hod T; Ben-David A; Olmer L; Levy I; Ghinea R; Mor E; Lustig Y; Rahav G
Transplantation; 2021 Nov; 105(11):e234-e243. PubMed ID: 34310101
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients.
Hirama T; Akiba M; Shundo Y; Watanabe T; Watanabe Y; Oishi H; Niikawa H; Okada Y
J Infect Chemother; 2022 Aug; 28(8):1153-1158. PubMed ID: 35599079
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
Shem-Tov N; Yerushalmi R; Danylesko I; Litachevsky V; Levy I; Olmer L; Lusitg Y; Avigdor A; Nagler A; Shimoni A; Rahav G
Br J Haematol; 2022 Feb; 196(4):884-891. PubMed ID: 34713441
[TBL] [Abstract][Full Text] [Related]
12. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
[TBL] [Abstract][Full Text] [Related]
13. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
Charmetant X; Espi M; Benotmane I; Barateau V; Heibel F; Buron F; Gautier-Vargas G; Delafosse M; Perrin P; Koenig A; Cognard N; Levi C; Gallais F; Manière L; Rossolillo P; Soulier E; Pierre F; Ovize A; Morelon E; Defrance T; Fafi-Kremer S; Caillard S; Thaunat O
Sci Transl Med; 2022 Mar; 14(636):eabl6141. PubMed ID: 35103481
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.
Khan QJ; Bivona CR; Martin GA; Zhang J; Liu B; He J; Li KH; Nelson M; Williamson S; Doolittle GC; Sun W; Mudaranthakam DP; Streeter NR; McGuirk JP; Al-Rajabi R; Hoffmann M; Kasi A; Parikh RA; Zhong C; Mitchell L; Pessetto ZY; Pathak H; Ghosh A; LaFaver S; Sharma P; Godwin AK
JAMA Oncol; 2022 Jul; 8(7):1053-1058. PubMed ID: 35446353
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM
JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765
[TBL] [Abstract][Full Text] [Related]
16. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
17. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
18. BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients.
Hod T; Ben-David A; Olmer L; Scott N; Ghinea R; Mor E; Levy I; Indenbaum V; Lustig Y; Grossman E; Rahav G
Transpl Int; 2022; 35():10239. PubMed ID: 35387393
[No Abstract] [Full Text] [Related]
19. Anti-spike antibody durability after SARS-CoV-2 vaccination in adolescent solid organ transplant recipients.
McAteer J; Kalluri DD; Abedon RR; Qin CX; Auerbach SR; Charnaya O; Danziger-Isakov LA; Ebel NH; Feldman AG; Hsu EK; Mohammad S; Perito ER; Thomas AM; Chiang TPY; Garonzik-Wang JM; Segev DL; Werbel WA; Mogul DB
Pediatr Transplant; 2024 Feb; 28(1):e14671. PubMed ID: 38317335
[TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience.
Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E
Front Immunol; 2022; 13():1049188. PubMed ID: 36505469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]